Alliance Wealth Advisors LLC Has $394,000 Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Alliance Wealth Advisors LLC cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 10.2% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,266 shares of the medical research company’s stock after selling 144 shares during the period. Alliance Wealth Advisors LLC’s holdings in Amgen were worth $394,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of AMGN. Tallon Kerry Patrick bought a new stake in Amgen in the fourth quarter valued at approximately $270,000. Brighton Jones LLC raised its stake in Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after buying an additional 5,226 shares during the period. Onyx Bridge Wealth Group LLC raised its stake in Amgen by 4.2% in the fourth quarter. Onyx Bridge Wealth Group LLC now owns 1,422 shares of the medical research company’s stock valued at $371,000 after buying an additional 57 shares during the period. Silver Oak Securities Incorporated increased its stake in shares of Amgen by 18.8% during the fourth quarter. Silver Oak Securities Incorporated now owns 1,691 shares of the medical research company’s stock worth $439,000 after purchasing an additional 268 shares during the period. Finally, Telos Capital Management Inc. increased its stake in shares of Amgen by 3.2% during the fourth quarter. Telos Capital Management Inc. now owns 25,997 shares of the medical research company’s stock worth $6,776,000 after purchasing an additional 797 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Up 1.1%

Shares of AMGN opened at $290.33 on Friday. The company has a market capitalization of $156.11 billion, a PE ratio of 38.45, a PEG ratio of 2.63 and a beta of 0.51. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The stock’s 50-day moving average price is $281.57 and its two-hundred day moving average price is $285.44. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The firm had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. During the same period last year, the company posted $3.96 EPS. The business’s quarterly revenue was up 9.4% on a year-over-year basis. On average, analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on AMGN shares. Bank of America increased their target price on Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a research note on Wednesday, March 5th. Mizuho increased their target price on Amgen from $235.00 to $280.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 7th. UBS Group reissued a “neutral” rating and set a $315.00 price target (down previously from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Erste Group Bank downgraded Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 8th. Finally, Royal Bank of Canada reduced their price target on Amgen from $324.00 to $320.00 and set an “outperform” rating on the stock in a research report on Friday, May 2nd. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $309.22.

Insider Activity at Amgen

In related news, SVP Rachna Khosla sold 1,500 shares of the business’s stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the sale, the senior vice president now directly owns 8,162 shares of the company’s stock, valued at $2,364,368.16. The trade was a 15.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.76% of the stock is currently owned by corporate insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.